A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
This is a very early study looking at a new medicine, PF-08046049/SGN-BB228, for people with advanced melanoma and other solid cancers such as bowel, lung, pancreatic cancer, and mesothelioma. It's called a Phase 1 study, which means it's the first time this drug is being given to people. The main goals are to check if the drug is safe, what side effects it might have, and how it behaves in the body. Researchers also want to find the best dose to use in future studies. This research could help doctors understand if this new drug has the potential to become a treatment option for these types of cancers.
Överblick
Vad handlar denna studie om?
This study is investigating a new potential cancer medicine known by its research name, PF-08046049/SGN-BB228. It's being tested in people who have advanced melanoma, which is a type of skin cancer, and other solid tumour cancers, including those affecting the pancreas, bowel (colorectal cancer), lungs (non-small cell lung cancer), and a rare cancer called mesothelioma.
This is a 'Phase 1' study, which is the very first step in testing a new drug in humans. The main purpose of this phase is not to cure cancer, but to carefully check the drug's safety, understand how the body handles it, and identify any side effects. Researchers will also be looking for the highest dose that can be given safely to patients. Think of it like taking the first few careful steps with a new medicine; it's about making sure it's safe to use before exploring how effective it might be.
By taking part, individuals contribute vital information that helps researchers decide if this new drug is promising enough to move on to larger studies. This kind of early research is crucial for developing new cancer treatments in the future, potentially offering new options where existing treatments might no longer be working.
Viktiga punkter
- This is an early-stage study for a new cancer drug.
- It's testing safety and how the drug works, not primarily aiming for a cure.
- It's for specific advanced cancers like melanoma, bowel, lung, and pancreatic cancer.
- Participation involves regular hospital visits for tests and medication.
- Potential for benefit and known risks of side effects will be discussed.
- Du kan dra dig ur studien när som helst.
Vem kan vara berättigad?
To be able to join this study, you generally need to be at least 18 years old. The study is open to both men and women.
Because this is a study for people with advanced cancer, you would need to have been diagnosed with one of the specific cancers being investigated, such as advanced melanoma, pancreatic cancer, bowel cancer, lung cancer (non-small cell type), or mesothelioma. Your doctors would need to confirm that your cancer fits the study's requirements.
There will also be other medical checks and criteria that your doctor will review to make sure this study is safe and appropriate for you. These might include your general health, how well your organs are working, and whether you've had certain treatments before. It's important to discuss all your medical history with the study team.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du 18 år eller äldre?
- Do you have advanced melanoma, pancreatic, bowel, lung (non-small cell), or mesothelioma cancer?
- Är du i allmänhet tillräckligt frisk för att delta i en studie?
- Are you able to attend regular hospital visits?
- Are you willing to follow the study's rules and schedules?
Vad innebär deltagande?
Taking part in this study would involve regular visits to the hospital or clinic. During these visits, you would have various assessments. These typically include physical examinations, blood tests and possibly urine tests, and scans (like CT scans) to monitor your health and how the treatment might be affecting your cancer. You would also be given the study medication, PF-08046049/SGN-BB228, which might be given as an infusion or in another form, depending on how the drug is designed. The study team will carefully explain the schedule for your medication.
Beyond these regular visits, there would also be follow-up appointments after you stop taking the study drug, to continue monitoring your health and any long-term effects. The total duration of your participation would vary depending on how you respond to the treatment and the specific study plan, but Phase 1 studies often involve a period of active treatment followed by monitoring.
Potentiella risker och fördelar
Platser (3)
- —ObekräftadFrankrike
- —ObekräftadItalien
- —ObekräftadTyskland
Vanliga frågor
Vad är en 'Fas 1'-studie?
A Phase 1 study is the very first time a new drug is given to people. It mainly checks if the drug is safe, what dose to use, and if it has any side effects.
Kommer detta läkemedel att bota min cancer?
The goal of this early study is not to cure cancer, but to understand if the drug is safe and how it works. It's a first step in developing new treatments.
What cancers does this study include?
It includes advanced melanoma, pancreatic, bowel, and lung cancer (non-small cell type), and mesothelioma.
Måste jag betala för att delta i studien?
No, you will not have to pay for the study drug or any study-related medical care.
Kan jag lämna studien när som helst?
Yes, you can choose to leave the study at any point, and your decision will not affect your usual medical care.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Intresserad av att delta?
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.